Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.51 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.49 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2450121 | 1.00 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL7634128 | 1.00 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL4184421 | 1.00 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL52420 | 1.00 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL8999525 | 0.97 | HIF1A (0.67) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL29466951 | 0.97 | HIF1A (0.74) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2446042 | 0.97 | HIF1A (0.74) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL29438162 | 0.97 | HIF1A (0.74) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL31447355 | 0.97 | HIF1A (0.74) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL6060987 | 0.95 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989110-B1 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL | Smart Brain Sro (CZ) | 2018-08-08 | — | — | EP | disclosed |
| US-9896466-B2 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level | KKCG AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20160075726-A1 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL | SPRINGTIDE VENTURES S.R.O. (CZ) | 2016-03-17 | — | — | US | disclosed |
| EP-2989110-A1 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL | Smart Brain S.r.o. (CZ) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014173374-A1 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL | Smart Brain s.r.o. (CZ) | 2014-10-30 | — | — | WO | disclosed |
| US-20110054212-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING PROCESS | OOHASHI HIDEKAZU | 2011-03-03 | — | — | US | disclosed |
| EP-1754597-B1 | Lithographic printing plate precursor and lithographic printing process | FUJIFILM CORP (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7851126-B2 | Including an aromatic diphosphonium compound along with an addition polymerization promoter, unsaturated compound, protective layeron an sluminium support; laser recording having excellent ink receptibility during printing and printing durability; strength; on-press development; image strength | FUJIFILM CORPORATION (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20070042293-A1 | Including an aromatic diphosphonium compound along with an addition polymerization promoter, unsaturated compound, protective layeron an sluminium support; laser recording having excellent ink receptibility during printing and printing durability; strength; on-press development; image strength | FUJI PHOTO FILM CO., LTD. | 2007-02-22 | — | — | US | disclosed |
| EP-1754597-A2 | Lithographic printing plate precursor and lithographic printing process | Fuji Photo Film Co., Ltd. (JP) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054212-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING PROCESS | FLNA, PFN1, FLNB | HIF1A 4296/4885ALDH1A1 4285/4885CYP1A2 3266/4885 |
| US-20160075726-A1 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL | ERBB2, EGFR, ERBB3 | HIF1A 1263/4885ALDH1A1 3053/4885CYP1A2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.